Figure 1. Bioinformatic analysis of 14-3-3ζ mRNA expression in NSCLC. (A) Expression of 14-3-3ζ mRNA in tumor tissues and adjacent non-tumor tissues (**P < 0.01 vs. adjacent normal lung tissues). (B and C) Expression of 14-3-3ζ transcripts in lung adenocarcinoma or squamous cell carcinoma and in corresponding normal lung tissue from UALCAN (B) and GEPIA (C) database. Relative expression of 14-3-3ζ was presented as the amount of 14-3-3ζ mRNA among one million transcripts (***P < 0.01 vs. normal lung tissue). (D) Log-rank survival analysis of NSCLC patients with different status of 14-3-3ζ. The red line indicates NSCLC patients with high expression of 14-3-3ζ, and the black line indicates those with low expression. Patients’ progression free survival (PFS), overall survival (OS), and post-progression survival (PPS) data in each cohort were presented along with the survival curve.